Abbreviations used:CAPE (CARD14-associated papulosquamous eruption), IL (interleukin), NF-κB (nuclear factor κ light-chain enhancer of activated B cells), PRP (pityriasis rubra pilari)
- CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B.J Biol Chem. 2001; 276: 11877-11882
- Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis.Am J Hum Genet. 2012; 90: 796-808
- PSORS2 is due to mutations in CARD14.Am J Hum Genet. 2012; 90: 784-795
- Familial pityriasis rubra pilaris is caused by mutations in CARD14.Am J Hum Genet. 2012; 91: 163-170
- Mutations in KDSR cause recessive progressive symmetric erythrokeratoderma.Am J Hum Genet. 2017; 100: 978-984
- Pityriasis rubra pilaris.Clin Exp Dermatol. 1980; 5: 105-112
- Epidemiology of psoriatic arthritis in the population of the United States.J Am Acad Dermatol. 2005; 53: 573
- The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.J Rheumatol. 2000; 27: 1247-1250
- Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study.Acta Derm Venereol. 2002; 82: 108-113
- Arthritis associated with pityriasis rubra pilaris.BMJ Case Rep. 2010; 2010https://doi.org/10.1136/bcr.12.2009.2565
- A review of pityriasis rubra pilaris and rheumatologic associations.Clin Dev Immunol. 2004; 11: 57-60
- Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14.Br J Dermatol. 2014; 171: 420-422
- CARD14 Glu138 mutation in familial pityriasis rubra pilaris does not warrant differentiation from familial psoriasis.J Dermatol. 2016; 43: 187-189
- Target-sequence capture and high throughput sequencing identify a de novo CARD14 mutation in an infant with erythrodermic pityriasis rubra pilaris.Acta Derm Venereol. 2016; 96: 989-990
- Autosomal dominant familial generalized pustular psoriasis caused by a CARD14 mutation.Br J Dermatol. 2017; 177: e133-e135
- Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14.Br J Dermatol. 2017; ([Epub ahead of print])https://doi.org/10.1111/bjd.15462
- Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-kappaB activation and endoplasmic reticulum stress-induced cell death.J Cell Physiol. 2011; 226: 3121-3131
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).Lancet. 2008; 371: 1675-1684
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).Lancet. 2008; 371: 1665-1674
- Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.J Am Acad Dermatol. 2010; 63: 571-579
- Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris.J Dermatol Case Rep. 2013; 7: 5-9
- Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy.Eur J Dermatol. 2010; 20: 630-631
- Treatment of pityriasis rubra pilaris with ustekinumab.Br J Dermatol. 2010; 163: 655-656
- Ustekinumab treatment of pityriasis rubra pilaris: a report of five cases.J Dermatol. 2018; 45: 202-206
- Ustekinumab as an alternative treatment option for chronic pityriasis rubra pilaris.Case Rep Dermatol. 2015; 7: 46-50
- Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris.JAMA Dermatol. 2017; 153: 304-308
Dr Craiglow and Boyden contributed equally to this work.
Drs Milstone and Paller also contributed equally.
Funding sources: Supported in part by National Institutes of Health (grants R01 AR068392 [to Dr Choate] and R01 AR050266 [to Dr Bowcock]), the Foundation for Ichthyosis and Related Skin Types and Dermatology Foundation (to Dr Craiglow), and the Yale Center for Mendelian Genomics (grant U54 HG006504).
Disclosure: Dr Choate has received honoraria from Janssen Biotech and Abbvie. Drs Craiglow, Boyden, Hu, Virtanen, Su, Rodriguez, McCarthy, Luna, Larralde, Humphrey, Holland, Hogeling, Hidalgo-Matlock, Ferrari, Fernandez-Faith, Drolet, Cordoro, Bowcock, Antaya, Ashack, Ashack, Lifton, Milstone, and Paller have no conflicts of interest to disclose.
Reprints not available from the authors.